Chemical inhibitors of transmembrane protein 262 can exert their inhibitory effects through various mechanisms implicating the alteration of cellular ion homeostasis and membrane potential. Ouabain and digoxin, for instance, target the Na+/K+-ATPase, which is a primary regulator of intracellular ion concentrations. By inhibiting this pump, these chemicals lead to an accumulation of sodium ions inside the cell, which can indirectly disturb the electrochemical gradient critical for the function of transmembrane protein 262. The disruption of this gradient is likely to hamper the protein's role in ion transport or the maintenance of membrane potential, which is essential for the normal function of many transmembrane proteins.
On the other hand, chemicals like Bafilomycin A1 and Concanamycin A, inhibitors of V-ATPases, can alter endosomal and lysosomal acidification. This can lead to the dysfunction of transmembrane protein 262 by impairing the protein's trafficking or localization, which often relies on the acidic environment of these organelles. Similarly, dynasore inhibits dynamin, pivotal for endocytosis and vesicle trafficking, and can inhibit the proper recycling or localization of transmembrane protein 262, thereby hindering its functional role. Genistein's inhibition of tyrosine kinases can prevent phosphorylation, a post-translational modification that transmembrane protein 262 may require for its activity. Chemicals such as Ionomycin and Thapsigargin disrupt calcium homeostasis, with Ionomycin increasing intracellular calcium by forming complexes with the ion, and Thapsigargin by inhibiting the SERCA pump, ultimately affecting calcium-dependent regulatory mechanisms of transmembrane protein 262. Monensin, by disrupting Na+/H+ exchange, and Niflumic Acid, by blocking chloride channels, both alter ion homeostasis, which could impede transmembrane protein 262 function that relies on maintaining specific ion concentrations or membrane potential. Lastly, Tetrodotoxin and Verapamil, which block sodium and calcium channels respectively, can inhibit transmembrane protein 262 through their effects on membrane potential and ion signaling, which are integral for the normal functioning of many transmembrane proteins, including transmembrane protein 262.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
Inhibits the Na+/K+-ATPase, which could lead to intracellular Na+ accumulation, affecting the Na+/Ca2+ exchanger activity indirectly. This could inhibit transmembrane protein 262 by altering ionic homeostasis across the membrane. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $140.00 $680.00 | ||
12β-Hydroxydigitoxin inhibits Na+/K+-ATPase. This inhibition could disrupt the electrochemical gradient, potentially inhibiting transmembrane protein 262's function related to ion transport or membrane potential maintenance. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Specifically inhibits V-ATPases, which could disrupt endosomal acidification and thus affect the trafficking or localization of transmembrane protein 262, leading to its functional inhibition. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Inhibits dynamin, which is involved in endocytosis and vesicle trafficking. This could inhibit the proper localization or recycling of transmembrane protein 262, leading to its functional inhibition. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Tyrosine kinase inhibitor which could inhibit phosphorylation events critical for the function of transmembrane protein 262, leading to its functional inhibition. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Inhibits V-ATPases like Bafilomycin A1, and thus could inhibit transmembrane protein 262 by disrupting vesicular acidification and associated trafficking processes. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore that disrupts calcium homeostasis. This could inhibit transmembrane protein 262 by altering calcium-dependent regulatory mechanisms essential for its function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
SERCA pump inhibitor, leads to increased cytosolic calcium levels, potentially inhibiting transmembrane protein 262 through dysregulation of calcium homeostasis. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
A sodium ionophore which disrupts Na+/H+ exchange and can alter intracellular pH. This could inhibit transmembrane protein 262 by disrupting the pH-dependent processes it may be involved in. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $31.00 | 3 | |
Blocks chloride channels which could inhibit transmembrane protein 262 by disrupting chloride ion homeostasis and membrane potential, potentially inhibiting its function. |